Dec. 16, 2021: ” Xeris Biopharma Holdings, Inc, a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that its commercialization partner, Tetris Pharma (Tetris), has launched Ogluo® (glucagon injection) in the United Kingdom and it is now available by prescription for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
In July, Xeris announced a licensing agreement with Tetris for the commercialization of Ogluo (European brand name of Gvoke®) in the European Union area, the UK, and Switzerland (the Territory).
Under the terms of the applicable agreements, Xeris is responsible for product supply and Tetris is responsible for the commercialization of Ogluo in the Territory, starting with the UK.
Tetris aims for Ogluo to be launched in several countries across Europe during 2022.
“Just as Gvoke has the potential to change lives for people in the US with diabetes, we are delighted that Ogluo is now accessible to people in the UK and will be available in other European countries in 2022,” said Paul R. Edick, Chairman and CEO of Xeris.
“Having a product that is ready-to-use will be a real benefit to both people with diabetes and their caregivers in the case of a severe hypoglycemic event.”
Xeris estimates there are approximately five million people with diabetes and at risk of severe hypoglycemia in the UK, with only an estimated 10-20% having a prescription for glucagon.
Healthcare professionals can obtain details about Ogluo® by emailing [email protected].
ABOUT GVOKE® (US) / OGLUO® (EU)
Gvoke® (glucagon injection), the first prescription, ready-to-use, pre-mixed, pre-measured glucagon injection, was approved by the FDA in September 2019 for use in the United States.
Gvoke is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.
Ogluo® (glucagon injection) received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in December 2020 and the European Commission (EC) granted the marketing authorization on 11 February 2021.
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) approved Ogluo on April 29, 2021. Ogluo is indicated for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.”
